Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Roivant Sciences Ltd WT (ROIVW)

Roivant Sciences Ltd WT (ROIVW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update GlobeNewswire - Tue Nov 12, 6:00AM CST

ROIVW : 2.75 (-3.85%)
ROIV : 11.16 (-0.36%)
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 GlobeNewswire - Tue Oct 29, 3:35PM CDT

ROIVW : 2.75 (-3.85%)
ROIV : 11.16 (-0.36%)
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% GlobeNewswire - Mon Oct 28, 8:25AM CDT

ROIVW : 2.75 (-3.85%)
ROIV : 11.16 (-0.36%)
Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022 Globe Newswire - Wed Aug 3, 2022

Investor call and webcast scheduled for Monday, August 15 at 8:00 a.m. EDTRoivant will host an investor day on Wednesday, September 28 at 11:00 a.m. EDT ...

ROIVW : 2.75 (-3.85%)
ROIV : 11.16 (-0.36%)
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update Globe Newswire - Tue Jun 28, 2022

Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical...

ROIVW : 2.75 (-3.85%)
ROIV : 11.16 (-0.36%)
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus Globe Newswire - Tue Jun 28, 2022

Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral...

ROIVW : 2.75 (-3.85%)
ROIV : 11.16 (-0.36%)
PFE : 24.86 (+0.24%)
Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022 Globe Newswire - Wed Jun 15, 2022

Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE...

ROIVW : 2.75 (-3.85%)
ROIV : 11.16 (-0.36%)
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years Globe Newswire - Tue May 24, 2022

- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically...

ROIV : 11.16 (-0.36%)
ROIVW : 2.75 (-3.85%)
Roivant to Present at Upcoming Investor Conferences Globe Newswire - Thu May 19, 2022

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming...

ROIVW : 2.75 (-3.85%)
ROIV : 11.16 (-0.36%)
Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting Globe Newswire - Fri Mar 25, 2022

Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated...

ROIV : 11.16 (-0.36%)
ROIVW : 2.75 (-3.85%)

Barchart Exclusives

Is It Time to Buy This Dividend Stock With Nuclear Energy Upside? Barchart - Mon Nov 18, 6:30PM CST
Apart from its prowess in nuclear energy, this energy company is also deploying AI. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot